High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 874-885

  Cook, Gordon ^a   Williams, Cathy ^b   Brown, Julia M ^c   Cairns, David A ^c   Cavenagh, Jamie ^d   Snowden, John A ^e   Ashcroft, A John ^f   Fletcher, Marie ^c   Parrish, Chris ^a   Yong, Kwee ^g   Cavet, Jim ^h   Hunter, Hanna ⁱ   Bird, Jenny M ^j   Chalmers, Anna ^c   O'Connor, Sheila ^a   Drayson, Mark T ^k   Morris, Treen C M ^l  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^j UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOPENIA; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SALVAGE THERAPY; SENSORY NEUROPATHY; SQUAMOUS CELL CARCINOMA; SUBARACHNOID HEMORRHAGE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED KINGDOM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NERVOUS SYSTEM DISEASES; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RECURRENCE; RETREATMENT; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84903531016     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70245-1     Document Type: Article

References (36)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97. for the Intergroupe Français du Myélome.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011, 154:32-75.
4. Ludwig H, Avet-Loiseau H, Bladé J, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012, 17:592-606.
5. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011, 29:1898-1906.
6. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1782-1791.
7. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085. for the GIMEMA Italian Myeloma Network.
8. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120:9-19.
9. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1770-1781.
10. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119:7-15.
11. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012, 120:1589-1596.
12. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012, 30:2946-2955.
13. Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013, 31:3279-3287.
14. Cook G, Liakopoulou E, Pearce R, et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011, 17:1638-1645.
15. Gonsalves WI, Gertz MA, Lacy MQ, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant 2013, 48:568-573.
16. Jimeney-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012, 18:773-779.
17. Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant 2013, 19:445-449.
18. Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013, 19:760-766.
19. Morris TCM, Iacobelli S, Brand R, et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a EBMT registry study. J Clin Oncol 2004, 22:1674-1681.
20. Morris C, Cook G, Streetly M, et al. Re-transplantation after bortezomib-based therapy. Br J Haematol 2011, 153:666-668.
21. Sellner L, Heiss C, Benner A, et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer 2013, 119:2438-2446.
22. Atanackovic D, Schilling G Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol 2013, 163:565-572.
23. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
24. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 National Cancer Institute, (accessed March 19, 2014). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3notice.pdf.
25. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
26. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012, 30:2475-2482.
27. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010, 303:1180-1187.
28. Korn EL, Freidlin B, Mooney M Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol 2009, 27:1712-1721.
29. Freidlin B, Korn EL Stopping clinical trials early for benefit: impact on estimation. Clin Trials 2009, 6:119-125.
30. Oakervee HE, Popat R, Curry N PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005, 129:755-762.
31. Kapoor P, Kumar SK, Dispenzieri A, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013, 31:4529-4535.
32. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013, 31:2540-2547.
33. Paiva B, Vidriales M-B, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
34. MacLennan ICM, Chapman C, Dunn J, Kelly K Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992, 339:200-205. for the Medical Research Council Working Party for Leukaemia in Adults.
35. Rosinol L, Oriol A, Teruel AI, et al. Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. alfa2b-interferon: final results of a phase III PETHEMA/GEM randomized trial. 54th American Society of Hematology Annual Meeting and Exposition; Atlanta, GA; Dec 8-11, 2012. Abstract 334.
36. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.